AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00891202 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration \<5 ng/mL: next higher dose administered; if >=5 ng/mL: same dose continued) at Week 41 \& Week 45, respectively.
Study NCT03951636 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Mechanical debridement with curettes
Description: mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments
Study NCT03951636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Er:YAG laser will be used for the implant surface decontamination.
Study NCT03951636 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air Powder
Description: mechanical debridement: Inflammatory tissue, excess cement or plaque deposits will be removed using hand instruments. Furthermore, an Air-Powder treatment will be provided on the implant/abutment surface.
Study NCT01495143 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterolateral lumbar fusion surgery
Description: Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.
Study NCT01495143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterolateral lumbar fusion surgery
Description: Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.
Study NCT02249637 — intervention group
Intervention type: PROCEDURE
Intervention: Novel technique Circumcision Incision Orchidopexy
Description: The novel technique starts with retraction of the prepucial skin off the glans penis and double incision circumcision done with mucosal sparing, then degloving of the penis on the side of the undescended testis. Dissection via Dartos' layer into the inguinal area until the palpable testicle was identified and extracted with mobilization of the spermatic cord. Hernia sac was then separated and suture ligated as high as the area of internal ring opening. Spematic cord lengthening was done until adequate length achieved for fixation into the inferior aspect of the scrotum. Then development of the Dartos' pouch via the circumcision site was done. A double or single suture testicular fixation using Vicryl 3-0 simple interrupted sutures on the everted Dartos' pouch inner surface was done. Subsequent placement of the testicle into the Dartos' pouch was done as the inner surface was inverted. The last step was the completion of the circumcision closure using Chromic 4-0 interrupted sutures.
Study NCT03648866 — intervention group
Intervention type: OTHER
Intervention: interview
Description: Initial interview and potential follow-up interviews and focus group with Florida Hospital employees.~Interview participants in compassion rounds
Study NCT00684177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retapamulin Ointment, 1%
Description: Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
Study NCT00684177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
Study NCT01446809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01446809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01446809 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy
Study NCT01446809 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy
Study NCT01446809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV
Study NCT01446809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ifosfamide
Description: Given IV
Study NCT01446809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01446809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01446809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT01446809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01446809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01446809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT01446809 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT01446809 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04175470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg intravenously every three weeks
Study NCT04175470 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: Capsules, 300 mg orally three times daily
Study NCT05114772 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Measuring Serum bio-markers
Description: ELISA Estimation of Serum visfatin and tumor necrosis factor-alpha
Study NCT03396770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard clinical routine
Description: Patient management is carried out according to the usual service protocol
Study NCT03396770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephrocheck test
Description: Nephrocheck® test is realized 4 hours after the end of the cardiopulmonary bypass~* If the test is positive, hemodynamic evaluation is carried out and adapted therapy to result of this evaluation is initiated.~* If the test is negative, patient management is carried out according to the usual protocol.~* A second test is realized 6 hours after the first test whatever the result of it.
Study NCT02363478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buspirone
Description: buspirone 10 mg X2 for 4 weeks
Study NCT03402776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4th dose of hexavalent vaccine 1 month after the 3rd dose
Description: 4th dose of hexavalent vaccine 1 month after the 3rd dose
Study NCT02424279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Splanchnicectomy
Study NCT04802473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mucogingival surgery
Description: In brief description, Tunnel+acellular dermal matrix treatment will be performed by starting initial sulcular incisions, tunneling knives will be used to elevate the buccal gingiva by means of a full-thickness flap elevation. Flap preparation will be extended beyond the MGJ. The exposed root surfaces will be treated with pre-conditioning EDTA (Straumann PrefGel®) for 2 minutes. ADM (OrACELL, LifeNet Helth, Virginia Beach, VA, USA) of 1.25-1.75mm in thickness will be cut to the exact size of the defect, and will be inserted into the tunnel, and subsequently covered advancing the flap by means of sling sutures to stabilize the flap in a coronal position (6-0 Polypropylene, Prolene, Ethicon, Johnson and Johnson, New Brunswick, NJ, USA). Sutures will be removed after 14 days. Two weeks after surgery, patients will resume mechanical tooth cleaning with a soft toothbrush. Patients will be recalled at 1, 3 and 6 months for professional oral hygiene procedures.
Study NCT01402245 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine
Description: Pneumococcal polysaccharide vaccine 0.5 ml i.m.
Study NCT01402245 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcal conjugate vaccine
Description: pneumococcal conjugate vaccine 0.5 ml i.m.
Study NCT01292967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low flavanol chocolate
Description: 48 mg of total flavanols from cocoa
Study NCT01292967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-flavanol with sugar
Description: high-flavanol containing 251 mg cocoa flavanols
Study NCT01292967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High flavanol Maltitol
Description: high-flavanol containing 266 mg cocoa flavanols
Study NCT03038308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Description: 0.25mg/day - 6.0mg/day oral non-ergoline dopamine agonist ropinirole
Study NCT04314050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: tramadol and paracetamol will perform
Study NCT04314050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine and paracetamol will perform
Study NCT04314050 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: paracetamol will perform
Study NCT04582760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early mobilization
Description: In patients who require mechanical ventilation for acute respiratory failure or sepsis (non-malignant tumor patients), early mobilization will be performed in addition to conventional bedside physical therapy, for 30 mins per session, two sessions per day, 7 days per week until the patients are discharged from the ICU.
Study NCT00544869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061 （Tolvaptan)
Description: 15-30mg/day,daily for 14days
Study NCT02077790 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: CASIA Cornea/Anterior Segment OCT SS-1000
Description: The SS-1000 is a three-dimensional, non-contact, non-invasive high resolution optical coherence tomography imaging device based on the principal of Swept Source OCT. The system achieves high resolution imaging of 10 μm (Axial) and 30 μm (Transverse) and high speed scanning of 30,000 A-scans per second.
Study NCT00771472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Parts I \& II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.
Study NCT01936220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuity of specialized care
Description: Continuity of care in treatment and professional caregiver was given during 5 year. Treatment targets included relapse prevention through recognition of prodromal symptoms, coping with negative symptoms and stress, increasing medication adherence, decrease of substance use, prevention of drop-out and stimulating and supporting participation in structural activities (work and/or education).
Study NCT01936220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent groups combined with Continuity of Specialized care
Description: Approximately fifty parent group therapy sessions will be held in a flexible way over a 60 month period. Each parent group was run by two experienced family therapists.
Study NCT01936220 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discontinuity of care, non specialised care
Description: Standard Treatment as usual (TU) was provided during 5 years by local mental health care professionals situated nearby the domicile of patients. TU had comparable treatment targets as ST but was not provided by treatment staff specialized in early intervention in schizophrenia or related disorders. However, TU was (like ST) sustained and dedicated to prevent psychotic relapse and improve social functioning.
Study NCT00667576 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Maxacalcitol
Description: Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
Study NCT00667576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
Study NCT04120558 — intervention group
Intervention type: OTHER
Intervention: Qualitative interviews and focus groups
Description: Semi-structured interviews will be undertaken with at least 24 and up to as many as 36 through knee and above knee amputees. A topic guide will be used to interview participants about perceived functional ability, body image, adapting post amputation and overall quality of life. A sampling frame will be used to ensure a range of views are sought (e.g. both men and women with through and above knee amputations; and with different mobility levels). Thematic analysis will be used to analyse the data. Focus group discussions will be informed by the findings of the interviews.~The themes that emerge from the semi-structured interviews will be further explored using focus groups and allow for comparison of the experiences between through knee and above knee amputees.
Study NCT04120558 — intervention group
Intervention type: OTHER
Intervention: Functional mobility tests and questionnaires
Description: Function in sitting and sit-and-reach will be assessed in non-ambulatory (wheelchair users) individuals. An overall score for each sitting activity will be recorded and the distance reached will be calculated.~Walking, timed-up-and-go, L-test, balance in sitting and standing, seated activities will be assessed in ambulatory (prosthetic using) individuals. The time taken, distance walked, distance reached, and the overall scores for each activity will be compared between the two groups. Fear of falls and confidence levels when performing tasks will be investigated using two questionnaires.~The EQ-5D-5L and SF-36 will be issued to the non-ambulatory and ambulatory participants to complete when attending the testing session.~The Locomotor Capability Index - 5 (LCI-5), Activities-specific Balance Confidence Scale (ABC-UK) and Houghton scale of prosthetic use in people with lower-extremity amputations
Study NCT03048955 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Superion® IDS
Description: Device is a non-fusion, spinal column load-sharing device used to stabilize the spine at the implanted leve
Study NCT03048955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct decompression Surgery
Description: A surgical procedure - the control
Study NCT00132041 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: radiofrequency ablation
Study NCT01483430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginseol Kg1 (low dose)
Description: 1 capsule/day (100mg of Ginseol Kg1), Duration: 8 weeks
Study NCT01483430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginseol Kg1(high dose)
Description: 1 capsule/day (300mg of Ginseol Kg1), Duration: 8 weeks
Study NCT01483430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule/day (starch), Duration: 8 weeks
Study NCT01171820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS® Liberté™
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
Study NCT01171820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V® EECSS
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
Study NCT02172157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL i.v.
Study NCT02172157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 1744 CL oral
Study NCT01358032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an in-home cognitive behavioral program
Description: The in-home cognitive behavioral program aims to learn older persons, living in the community, how to deal with concerns about falling and to increase physical, social and functional activity. The principles of cognitive restructuring are used for shifting maladaptive in adaptive attitudes with respect to falling as well as increasing self efficacy beliefs and feelings of control. The following themes are discussed during the program: concerns about falling, thoughts about falling, physical exercise, assert oneself, overcome personal barriers, recognizing fall-ty habits and managing concerns about falling. Duration of the program is 10 weeks with 7 individual sessions (3 home visits (60, 60 and 75 minutes, respectively) \& 4 telephone contacts (35 minutes each). The program is facilitated by trained nurses qualified in the field of geriatrics and working for home care agencies.
Study NCT00483886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 2 mg o.d.
Study NCT00483886 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo o.d.
Study NCT00483886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 4 mg o.d.
Study NCT02780076 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional training program
Description: Patients treated for hip fracture participate in a functional training program during their short-term stays at nursing homes. The program is initiated by the nurses 4 times a day for 3 weeks as part of the habitual routine.
Study NCT00956943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicoderm CQ transdermal nicotine
Description: Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
Study NCT00956943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicoderm CQ transdermal nicotine
Description: Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
Study NCT00956943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo patch
Study NCT03706703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: continuous intravenous infusion Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
Study NCT03706703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel is 75 mg/m2 intravenously over 1 hour on Day 1 of each 21-day cycle
Study NCT03706703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin is administered on Day 1 of each 21-day，followed by docetaxol or pemetrexed
Study NCT03706703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: pemetrexed is 500 mg/m2 intravenously on Days 1 of each 21-day cycle
Study NCT00809328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.
Study NCT01172756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: 0.5 mg single oral dose
Study NCT01172756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: 1 mg single oral dose
Study NCT01172756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: 2 mg single oral dose
Study NCT01172756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single oral dose
Study NCT02020044 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Endothelial Keratoplasty
Study NCT05055232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-3621
Description: tablets, dosage ranged from 50 mg to 600 mg, quaque die（QD）with the meal.
Study NCT03125278 — intervention group
Intervention type: OTHER
Intervention: Medication knowledge
Description: Participants will be asked questions over the phone about their medications
Study NCT00690651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early mobilization
Description: pt to get out of bed and mobilize with physiotherapist within 24 hours of surgery. they will be allowed toilet privileges and will go home when safe (as per medical staff and allied health)
Study NCT02140255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Description: Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.